Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous FormulationMasaaki Yoshikawa, Haruki Koike, Yukako Inoue et al.|Neurology and Therapy|2025Cited by 13
Hypertension, cerebral Amyloid, aGe Associated Known neuroimaging markers of cerebral small vessel disease Undertaken with stroke REgistry (HAGAKURE) prospective cohort study: Baseline characteristics and association of cerebral small vessel disease with prognosis in an ischemic stroke cohortShuhei Ikeda, Hideo Hara, Chika Shichijo et al.|Frontiers in Aging Neuroscience|2023Cited by 8
Cerebral small vessel disease markers and long-term prognosis in spontaneous intracerebral hemorrhage: the HAGAKURE-ICH studyShuhei Ikeda, Hideo Hara, Yusuke Yakushiji et al.|Hypertension Research|2024Cited by 6
Efgartigimod Successfully Ameliorated Acute Exacerbation of Myasthenia Gravis with Anti-muscle-specific Kinase AntibodiesKoya Tanaka, Haruki Koike, Masaaki Yoshikawa et al.|Internal Medicine|2024Cited by 4
Characteristics of meningitis/encephalitis in adult patients with varicella-zoster virus infection: Experience from tertiary centers in Saga prefecture, JapanKeisuke Tsumura, Haruki Koike, Yukako Inoue et al.|Journal of the Neurological Sciences|2025Cited by 2